Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics
Background: Severe mental illnesses are associated with increased risks for metabolic syndrome (MetS) and other medical disorders, often with unfavorable outcomes. MetS may be more likely with schizoaffective disorder (SzAff) than schizophrenia (Sz). MetS is associated with long-term antipsychotic d...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-01-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2018.00744/full |
| _version_ | 1811323663019933696 |
|---|---|
| author | Antonio Ventriglio Ross J. Baldessarini Ross J. Baldessarini Giovanna Vitrani Iris Bonfitto Angela Chiara Cecere Angelo Rinaldi Annamaria Petito Antonello Bellomo |
| author_facet | Antonio Ventriglio Ross J. Baldessarini Ross J. Baldessarini Giovanna Vitrani Iris Bonfitto Angela Chiara Cecere Angelo Rinaldi Annamaria Petito Antonello Bellomo |
| author_sort | Antonio Ventriglio |
| collection | DOAJ |
| description | Background: Severe mental illnesses are associated with increased risks for metabolic syndrome (MetS) and other medical disorders, often with unfavorable outcomes. MetS may be more likely with schizoaffective disorder (SzAff) than schizophrenia (Sz). MetS is associated with long-term antipsychotic drug treatment, but relative risk with orally administered vs. long-acting injected (LAI) antipsychotics is uncertain.Methods: Subjects (n = 151 with a DSM-IV-TR chronic psychotic disorder: 89 Sz, 62 SzAff), treated with oral or LAI antipsychotics were compared for risk of MetS, initially with bivariate comparisons and then by multivariate regression modeling.Results: Aside from measures on which diagnosis of MetS is based, factors preliminarily associated with MetS included antipsychotic drug dose, “high-risk” antipsychotics associated with weight-gain, older age and female sex. Defining factors associated with diagnosis of MetS ranked in multivariate regression as: higher fasting glucose, lower LDL cholesterol, higher diastolic blood pressure, and higher BMI. Risk of MetS with antipsychotics ranked: quetiapine ≥ clozapine ≥ paliperidone ≥ olanzapine ≥ risperidone ≥ haloperidol ≥ aripiprazole. Other associated risk factors in multivariate modeling ranked: higher antipsychotic dose, older age, and SzAff diagnosis, but not oral vs. LAI antipsychoticsConclusions: SzAff diagnosis and higher antipsychotic doses were associated with MetS, whereas orally vs. injected antipsychotics did not differ in risk of MetS. |
| first_indexed | 2024-04-13T13:59:13Z |
| format | Article |
| id | doaj.art-e7ba433e2c6f4414b967b9a96f82ae7b |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-04-13T13:59:13Z |
| publishDate | 2019-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-e7ba433e2c6f4414b967b9a96f82ae7b2022-12-22T02:44:06ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402019-01-01910.3389/fpsyt.2018.00744420597Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected AntipsychoticsAntonio Ventriglio0Ross J. Baldessarini1Ross J. Baldessarini2Giovanna Vitrani3Iris Bonfitto4Angela Chiara Cecere5Angelo Rinaldi6Annamaria Petito7Antonello Bellomo8Department of Clinical and Experimental Medicine, University of Foggia, Foggia, ItalyInternational Consortium for Psychotic & Mood Disorder Research, McLean Hospital, Belmont, MA, United StatesDepartment of Psychiatry, Harvard Medical School, McLean Hospital, Boston, MA, United StatesDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, ItalyDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, ItalyDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, ItalyDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, ItalyDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, ItalyDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, ItalyBackground: Severe mental illnesses are associated with increased risks for metabolic syndrome (MetS) and other medical disorders, often with unfavorable outcomes. MetS may be more likely with schizoaffective disorder (SzAff) than schizophrenia (Sz). MetS is associated with long-term antipsychotic drug treatment, but relative risk with orally administered vs. long-acting injected (LAI) antipsychotics is uncertain.Methods: Subjects (n = 151 with a DSM-IV-TR chronic psychotic disorder: 89 Sz, 62 SzAff), treated with oral or LAI antipsychotics were compared for risk of MetS, initially with bivariate comparisons and then by multivariate regression modeling.Results: Aside from measures on which diagnosis of MetS is based, factors preliminarily associated with MetS included antipsychotic drug dose, “high-risk” antipsychotics associated with weight-gain, older age and female sex. Defining factors associated with diagnosis of MetS ranked in multivariate regression as: higher fasting glucose, lower LDL cholesterol, higher diastolic blood pressure, and higher BMI. Risk of MetS with antipsychotics ranked: quetiapine ≥ clozapine ≥ paliperidone ≥ olanzapine ≥ risperidone ≥ haloperidol ≥ aripiprazole. Other associated risk factors in multivariate modeling ranked: higher antipsychotic dose, older age, and SzAff diagnosis, but not oral vs. LAI antipsychoticsConclusions: SzAff diagnosis and higher antipsychotic doses were associated with MetS, whereas orally vs. injected antipsychotics did not differ in risk of MetS.https://www.frontiersin.org/article/10.3389/fpsyt.2018.00744/fullmetabolic syndromeantipsychoticslong-acting injectedschizoaffectiveschizophrenia |
| spellingShingle | Antonio Ventriglio Ross J. Baldessarini Ross J. Baldessarini Giovanna Vitrani Iris Bonfitto Angela Chiara Cecere Angelo Rinaldi Annamaria Petito Antonello Bellomo Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics Frontiers in Psychiatry metabolic syndrome antipsychotics long-acting injected schizoaffective schizophrenia |
| title | Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics |
| title_full | Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics |
| title_fullStr | Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics |
| title_full_unstemmed | Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics |
| title_short | Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics |
| title_sort | metabolic syndrome in psychotic disorder patients treated with oral and long acting injected antipsychotics |
| topic | metabolic syndrome antipsychotics long-acting injected schizoaffective schizophrenia |
| url | https://www.frontiersin.org/article/10.3389/fpsyt.2018.00744/full |
| work_keys_str_mv | AT antonioventriglio metabolicsyndromeinpsychoticdisorderpatientstreatedwithoralandlongactinginjectedantipsychotics AT rossjbaldessarini metabolicsyndromeinpsychoticdisorderpatientstreatedwithoralandlongactinginjectedantipsychotics AT rossjbaldessarini metabolicsyndromeinpsychoticdisorderpatientstreatedwithoralandlongactinginjectedantipsychotics AT giovannavitrani metabolicsyndromeinpsychoticdisorderpatientstreatedwithoralandlongactinginjectedantipsychotics AT irisbonfitto metabolicsyndromeinpsychoticdisorderpatientstreatedwithoralandlongactinginjectedantipsychotics AT angelachiaracecere metabolicsyndromeinpsychoticdisorderpatientstreatedwithoralandlongactinginjectedantipsychotics AT angelorinaldi metabolicsyndromeinpsychoticdisorderpatientstreatedwithoralandlongactinginjectedantipsychotics AT annamariapetito metabolicsyndromeinpsychoticdisorderpatientstreatedwithoralandlongactinginjectedantipsychotics AT antonellobellomo metabolicsyndromeinpsychoticdisorderpatientstreatedwithoralandlongactinginjectedantipsychotics |